While an essential role of HIV-1 integrase (IN) 
INTRODUCTION
HIV-1 integrase (IN) catalyzes the covalent insertion of the reverse transcribed viral genome into the host chromosome during the early steps of HIV-1 infection. A tetramer of IN binds both double stranded viral DNA ends to form the stable synaptic complex (SSC) and associates with cellular protein LEDGF/p75, which both enhances integration efficiency and preferentially guides HIV-1 integration to actively transcribed genes (reviewed in Debyser et al., 2015; Engelman and Cherepanov, 2008) . The catalytic activity of IN has been exploited as a therapeutic target and three Food and Drug Administration (FDA)-approved inhibitors (raltegravir, elvitegravir, and dolutegravir) have witnessed widespread clinical success.
Mutational studies have unexpectedly revealed that various substitutions in the IN coding region can influence not only integration but also other viral replication steps (reviewed in Engelman, 1999) . Therefore, IN mutations have been grouped into two general classes: substitutions that selectively impair integration have been assigned to class I and IN mutants that adversely affect multiple steps of virus replication have been grouped as class II (reviewed in Engelman, 1999) . Some class II IN mutations impair correct virus particle maturation during the late stage of replication. A hallmark of this phenotype is the mislocalization of the ribonucleoprotein complexes (RNPs) to an eccentric position between the empty capsid (CA) core and the particle membrane in mature virions, whereas normal virions contain RNPs within the CA core. For the past 20 years it has remained enigmatic as to how IN could contribute to proper viral particle maturation.
Allosteric IN inhibitors (ALLINIs, which are also known as LEDGINs, NCINIs, or INLAIs) have recently emerged as a promising class of antiretroviral agents and select compounds are currently in clinical trials (Christ et al., 2010; Fader et al., 2014; Gupta et al., 2014; Kessl et al., 2012; Le Rouzic et al., 2013; van Bel et al., 2014) . ALLINIs bind at the IN catalytic core domain (CCD) dimer interface and induce aberrant IN multimerization. Unexpectedly, ALLINIs potently impair the late stage of HIV-1 replication. In particular, these inhibitors selectively interfere with proper virus particle maturation and yield non-infectious particles with eccentrically positioned RNPs closely resembling those seen for certain class II IN mutants (Balakrishnan et al., 2013; Desimmie et al., 2013; Fontana et al., 2015; Jurado et al., 2013) . However, it is unclear how ALLINIs, through the promotion of aberrant IN multimerization, adversely affect virion maturation and result in the mislocalization of the RNPs outside the CA core.
These observations prompted us to test the hypothesis that HIV-1 IN interacts with the viral RNA (vRNA) genome in virions and that these interactions are essential for correct viral particle morphogenesis. Further rationale for this notion was provided by an earlier study that had selected RNA oligonucleotides from a random pool of in vitro transcribed molecules of artificial sequences and showed that they can bind recombinant HIV-1 IN with high affinity (Allen et al., 1995) . However, it remained unknown whether IN can interact with RNA in virions. To examine this possibility we have employed a crosslinking-immunoprecipitation sequencing (CLIP-seq) approach (Kutluay et al., 2014) , which allows for the identification of RNA molecules bound by an RNA-binding protein of interest in physiologically relevant settings at near-nucleotide resolution. Our results have revealed that HIV-1 IN binds to the viral RNA genome in virions and that ALLINIs inhibit these interactions.
RESULTS

HIV-1 Integrase Binds the Viral RNA Genome in Virions
To examine whether IN is bound to RNA in virions we carried out CLIP-seq experiments (Kutluay et al., 2014) with wild-type (WT) HIV-1 NL4-3 . Incorporation of 4-thiouridine (4SU) in the nascent RNAs allowed us to crosslink interacting protein-RNA complexes. Subsequent immunoprecipitation with IN antibody followed by autoradiography revealed the IN-RNA adducts (Figure 1A) indicating that IN is directly bound to RNA in virions. The IN-RNA adducts were not seen in control experiments with HIV-1 NL4-3 DIN , which yields eccentric, non-infectious virions (Bukovsky and Gö ttlinger, 1996; Engelman et al., 1995; Jurado et al., 2013) . CLIP-seq analysis allowed us to identify crosslinking sites in RNA by the appearance of T to C mutations arising during reverse transcription. Figure 1B shows that $95% of IN-bound RNAs were derived from viral RNAs, whereas a much smaller fraction ($5%) was of cellular origin. The higher levels of IN binding to viral versus cellular RNA seen in our CLIP-seq experiments is consistent with the enriched levels of viral ($80%) versus cellular ($20%) RNA present in virions as determined by RNA sequencing (RNA-seq) (Kutluay et al., 2014) . In parallel control experiments, only residual reads were seen with virions produced from HIV-1 NL4-3 DIN ( Figure 1C ). Importantly, IN binding to the viral RNA genome was not uniform across the viral sequence but instead displayed evidence of selectivity with highly reproducible binding sites evident at numerous discrete positions across the genome ( Figure S1 ).
Comparison of binding sites along the viral genome in virions identified by CLIP-seq approaches for IN and previously reported NC (Kutluay et al., 2014) revealed distinct binding patterns for these two proteins ( Figures S2A and S2B ). For example, IN but not NC showed a strong preference for binding the transactivation response (TAR) element (peak centered on nucleotide position 30) ( Figure S2C ). In contrast, IN did not bind the Psi packaging element (peak centered on nucleotide position 337), a preferred binding region for NC ( Figure S2C ). Additionally, differential binding by NC and IN was evident in most other regions of the viral RNA genome (Figures S2D-S2F ). Both IN and NC interacted with the rev response element (RRE), but the local binding sites of these proteins within this RNA structural element exhibited both similarities and differences ( Figure S2F (Figure 2A ), which had been used to monitor IN binding to synthetic viral DNA ($1 kbp) (Kessl et al., 2011) . Unliganded IN is retained by the SEC column after centrifugation ( Figure 2B , lane 3), whereas larger complexes including unbound nucleic acids and nucleic acids in the complex with IN are excluded from the column. Using this approach, we examined two reaction conditions. Duplicate IN-nucleic acid complexes were formed in the physiologically relevant (100 mM NaCl) ionic strength buffer. After complex formation, one set of samples was adjusted to higher ionic strength buffer (1 M NaCl). Both conditions were then subjected to SEC in their corresponding buffer ( Figure 2B ). Under physiologically relevant conditions IN was excluded from the column in the presence of viral DNA or viral RNA ( Figure 2B , lanes 4 and 5) indicating that IN binds either nucleic acid. However, in samples subjected to higher ionic strength buffer prior to SEC, the SSC formed between IN and viral DNA remained intact, as expected ( Figure 2B , lane 6) (Kessl et al., 2011; Kotova et al., 2010) , whereas the preformed IN-viral RNA complex dissociated ( Figure 2B, lane 7) .
To determine the relative binding affinity of recombinant WT IN for various viral RNA structural elements and cellular RNAs we have developed an AlphaScreen approach ( Figure 2C ). We first examined IN binding to several structurally distinct viral RNA elements of similar nucleotide length derived from the 5 0 -UTR. The AlphaScreen binding assay demonstrated a tight interaction between IN and vRNA(1-57)-TAR in physiologically relevant ionic strength buffer of 0.1 M NaCl ( Figure 2D ). In agreement with the SEC data, high ionic strength buffers (1 M NaCl) abolished IN-vRNA(1-57)-TAR binding ( Figure 2D ). Figure 2E shows that IN bound to vRNA(1-57)-TAR with significantly higher affinity (2.8 ± 0.4 nM) than vRNA(58-104)-polyadenylation signal (poly-A), vRNA(237-279)-dimerization initiation sequence (DIS), vRNA(278-305)-splice donor (SD), or vRNA(311-336)-Psi. Overall, these in vitro findings are consistent with the IN binding pattern seen in CLIP-seq experiments ( Figures 1C, S1 , and S2).
We used the vRNA(1-57)-TAR segment as an example to dissect whether IN exhibits preference for certain RNA nucleotide sequence and/or structural features ( Figure S3 ). Because CLIP-seq data ( Figures 1C, S2C , and S3) revealed that nucleotide 30, located in the loop of TAR, was the primary 4SU nucleotide binding site (accounting for $80% of T-to-C conversions within TAR) to IN (Figure S3A ), our mutagenesis experiments targeted the loop and adjacently located 3-nt bulge of TAR ( Figure S3B ). Deletions of these structural elements reduced the IN binding affinity to vRNA(1-57)-TAR by $14-fold while substitutions in the loop and 3-nt bulge did not significantly compromise IN binding to vRNA(1-57)-TAR ( Figure S3C ). Furthermore, the Tat-derived L50 peptide (Athanassiou et al., 2007) , which selectively engages both the loop and 3-nt bulge but not the double stranded stem of TAR, potently inhibited IN binding to vRNA(1-57)-TAR ( Figure S3D ). Collectively, these results indicate that IN displays a preference for select structural RNA elements of vRNA(1-57)-TAR including the adjacently located loop and 3-nt bulge, as opposed to a specific nucleotide sequence. Furthermore, these in vitro findings are in excellent agreement with the CLIP-seq results which identified the TAR loop as a major binding site for IN (Figures 1C, S1 , and S2).
Next, we compared the relative binding affinities of IN to larger RNA segments of viral and cellular origin ( Figure 2F ). Due to the varying length of different RNAs used in these experiments, we normalized the binding affinities based on the overall nucleotide concentration in the reaction. IN bound with similar affinities to vRNA(1-850) and vRNA(7350-8200) containing TAR and RRE, respectively. However, IN exhibited $8-, 16-, and 180-fold reduced affinities for human mRNA mix, yeast tRNA mix, and human tRNA Lys , respectively ( Figure 2F ).
IN Modulates RNA Structure In Vitro
To examine whether IN can affect RNA structure, we monitored the interaction of recombinant full-length WT IN with in vitro transcribed vRNA(1-850) using atomic force microscopy (AFM) (Figures 3 and S3) . Figures 3A and S3E show that IN alone did not yield any detectable signal, whereas vRNA(1-850) molecules were uniformly dispersed ( Figures 3B and S3F ). The measured vRNA(1-850) volumes were compatible with predicted in silico calculations ( Figure S3H ). Strikingly, AFM images of IN-vRNA(1-850) complexes markedly differed in both shape and size compared to unliganded vRNA(1-850) (compare Figure 3C with 3B and Figure S3G with S3F Figure 3D ) corresponded to the sizes of dimers or tetramers ( Figure S3I ).
To evaluate the stoichiometry of interactions, we added a molar excess of IN to vRNA(1-850) and subjected the complex to SEC to remove unbound protein ( Figure 2B ). Immunoblotting ( Figure 2B ) and AFM (Figures 3C and S3G) analysis confirmed that purified samples contained IN-vRNA(1-850) complexes and not unbound . Examination of the purified complex in six independent experiments by immunoblotting for IN and UV spectroscopy (OD 260 nm ) for RNA indicated a ratio of $4 IN per one vRNA(1-850) molecule ( Figure S3J ).
Because these data suggested that IN bridges separate RNA molecules, we developed an AlphaScreen-based RNA bridging assay ( Figure 3E ). This approach is complementary to the AFM experiments, which used longer vRNA(1-850) ( Figure 3C ), as the RNA bridging assay utilized short vRNA(1-57)-TAR oligonucleotides to avoid potential non-specific RNA coating-induced complex aggregation. Furthermore, we varied the IN concentration from 0 nM to 1,600 nM to delineate whether RNA bridging could be induced by soluble low-order oligomeric forms and/or higher order aggregates of the protein ( Figure 3F ). For example, in our reaction conditions containing 100 mM NaCl, 10 to 100 nM IN constitutes a range of soluble low-order oligomers such that monomeric IN predominates at the lower concentrations and dimeric and tetrameric forms prevail with increasing IN concentrations (Deprez et al., 2000) . However, subsequent increased concentrations of IN, in the same physiologically relevant buffer causes the formation of higher order aggregates (Deprez et al., 2000) . Figure 3F revealed a bell-shaped dose response curve where the AlphaScreen signal increased markedly with increasing IN concentrations up to 100 nM, corresponding to increasing dimeric and tetrameric forms of IN. In contrast, subsequent increases of IN concentrations, corresponding to increased higher order aggregates, yielded reduced AlphaScreen signal. Of note, parallel experiments with reverse transcriptase (RT) protein did not yield any detectable AlphaScreen signal, indicating that this RNA binding viral protein was unable to bridge two RNA molecules ( Figure 3F ). These results corroborate the AFM results ( Figures 3C and 3D ) and indicate that only soluble low-oligomeric forms (dimers and tetramers) of IN rather than higher order aggregates are capable of bridging RNA molecules.
The above findings suggested the possibility that RNA binding might stabilize functional low-order oligomeric forms of IN. The rationale for this idea is based on the fact that unliganded HIV-1 IN is poorly soluble, but LEDGF/p75 has been shown to stabilize a soluble IN tetramer both in vitro and in cells (Llano et al., 2006; McKee et al., 2008) . While experiments with LEDGF/p75 knockout cells have demonstrated the key role of this chromatin bound protein during HIV-1 integration, LEDGF/ p75 is fully dispensable during particle morphogenesis as virions produced in the presence or absence of LEDGF/p75 are equally infectious (Fadel et al., 2014 . The Lys residues that are surface exposed in both unliganded IN and the IN-vRNA(1-57)-TAR complex are readily modified by NHS-biotin, whereas the residues that engage viral RNA are shielded from the modification in the nucleoprotein complex. We detected modifications of 12 Lys residues (K14, K159, K160, K186, K215, K219, K244, K258, K264, K266, K266, and K273) in unliganded IN. Strikingly, only three adjacently located Lys residues (K264, K266, and K273) were protected in the presence of viral RNA ( Figure 4 ). To verify the significance of identified IN residues for viral RNA binding we prepared two mutant recombinant INs containing either K264A/K266A or R269A/K273A substitutions. R269A was included in our mutagenesis studies due to its adjacent location with the identified Lys residues and a high degree of conservation among different HIV-1 variants. In vitro AlphaScreen assays revealed that both K264A/K266A and R269A/K273A INs failed to bind vRNA(1-57)-TAR ( Figure 5A ). Given the pleiotropic nature of many IN mutations (Engelman, 1999; Rihn et al., 2015) , we also examined the effects of K264A/ K266A and R269A/K273A substitutions on other functions of the recombinant protein. WT and R269A/K273A INs exhibited a very similar multimerization pattern with clearly separated tetrameric and monomeric peaks detected by SEC ( Figure 5B ). K264A/ K266A IN also displayed tetrameric and monomeric peaks but had a slightly broader shoulder between the two peaks, possibly due to higher content of a dimeric form. WT, K264A/ K266A and R269A/K273A INs similarly bound to LEDGF/p75 ( Figure 5C ). Figure 5D shows that IN R269A/K273A efficiently catalyzed LEDGF/p75-dependent concerted integration in vitro, whereas IN K264A/K266A was inactive. In summary, the K264A/K266A substitutions displayed pleiotropic effects, whereas R269A/K273A IN was selectively impaired for RNA binding without significantly affecting other known functions of the protein in vitro.
IN Mutants Impaired for Viral RNA Binding Yield Viral Particles with Eccentric RNPs
We next introduced IN K264A/K266A and R269A/K273A substitutions in HIV-1 NL4-3 to examine their effects on HIV-1 replication and IN binding to RNA in virions. These amino acid changes did not detectably affect proteolytic processing of HIV-1 polyproteins ( Figure S4A ), genomic RNA packaging ( Figure S4B ) or particle release ( Figure S4C ). However, these particles were not infectious ( Figure S4D ) and failed to initiate reverse transcription in target cells ( Figure S4E ).
CLIP-seq experiments with virions isolated from producer cells transfected with HIV-1 NL4-3 IN(K264A/K266A) or HIV-1 NL4-3 IN(R269A/K273A) revealed that these substitutions greatly reduced IN binding to the viral RNA genome in virions ( Figures 6A and 6B ). Importantly, this finding was not due to reduced levels of IN protein in virions ( Figure 6A ). Moreover, and in sharp contrast, comparable levels of NC-RNA complexes were detected in virions of WT and IN mutant viruses ( Figure 6A ).
Further inspection of HIV-1 NL4-3 IN(K264A/K266A) and HIV-1 NL4-3 IN(R269A/K273A) particles with electron microscopy revealed eccentric cores with the characteristic class II phenotype where the electron dense material corresponding to RNPs was mislocalized outside of the translucent CA cores ( Figure 6C ). Sucrose density gradient fractionation experiments (Figures 6D and 6E) reproducibly corroborated these findings; WT CA cores containing the RNPs migrated to higher density fractions compared with CA cores isolated from HIV-1 NL4-3 IN(K264A/K266A) or HIV-1 NL4-3 IN(R269A/K273A) particles, which did not contain RNPs ( Figure 6C ) and were found in lower density fractions (Figures 6D and 6E) . inhibitor BI-B2 (also known as ALLINI-2) ( Figure S7A ) in conjunction with the WT virus and HIV-1 NL4-3 IN(A128T) , a mutation that confers significant resistance to this inhibitor ( Figure 7A ) Fontana et al., 2015; Shkriabai et al., 2014) . BI-B2 treatment of virus producer cells substantially inhibited the binding of WT IN to RNA in virions, while the treatment of HIV-1 NL4-3 IN(A128T) with the inhibitor yielded IN-RNA crosslink levels that were comparable with untreated WT virus ( Figures  7B and S7B ). Further analysis of CLIP-seq data revealed that BI-B2 treatment of cells producing HIV-1 NL4-3 blocked the binding of WT IN throughout the entire viral genome, while virions isolated from BI-B2-treated cells producing HIV-1 NL4-3 IN(A128T) displayed the characteristic pattern of WT IN interaction with the viral RNA genome ( Figure 7C ).
In addition, we have analyzed another potent ALLINI BI-D (Figure S7A) , which unlike BI-B2 retains significant antiviral activity with respect to HIV-1 NL4-3 IN(A128T) (Le Rouzic et al., 2013) . In full agreement with the antiviral activity results, BI-D impaired IN binding to RNA in virions from both WT and IN A128T mutant viruses ( Figure S7B ). Importantly, neither BI-B2 nor BI-D had any detectable effects on NC binding to RNA in mature virions (Figures 7B and S7C) .
DISCUSSION
We present five key findings in our present study. During particle maturation, viral PR cleaves Gag-Pol and Gag polyproteins into individual domains, triggering profound structural rearrangements within the virion and leading to the RNPs being localized into the conical CA core. The RNPs contain two copies of viral genome, some cellular RNAs, a number of viral proteins including NC, IN, and RT as well as a subset of cellular proteins. While the role of NC in the condensation of RNPs has been widely accepted (Mori et al., 2015) , many of the mechanistic details and molecular interactions required for correct viral particle morphogenesis are poorly understood. Our results show that when IN binding to viral RNA is impaired by IN R269A/K273A mutations (that do not affect any other known function of the protein) or ALLINI treatment, the resulting virions contain WT levels of NC-RNA complexes in eccentrically mislocalized RNPs. This finding demonstrates that the assembly of NC-RNA complexes, while essential, is not sufficient for correct virion morphogenesis and that IN binding to the viral RNA genome is also likely important for formation of infectious virions. We suggest that IN interactions with the viral RNA genome has the following dual roles: (1) IN binding to viral RNA ensures the incorporation of this viral protein within the protective CA core and stabilizes low-oligomeric forms of IN, which is likely to be essential for its function during subsequent infection when it forms the catalytically active SSC with viral DNA in target cells; and (2) in turn, IN contributes to the formation of the correct architecture and/or localization of RNPs within matured, infectious virions.
In vitro experiments with recombinant IN and NC have been instrumental to understand the mechanistic basis of their binding to model nucleic acids (reviewed in Cherepanov et al., 2011; Mori et al., 2015) . In order to induce effective aggregation of the nucleoprotein complexes, NC is typically added at a ratio that would allow for NC to cover the entire nucleic acid with each molecule occupying $7 nts segment. In contrast, IN does not coat viral RNA, even when added in significant excess, as evidenced by the stoichiometry of approximately four subunits of IN bound per one molecule of vRNA(1-850). Instead, IN appears to provide nucleation points by bridging separate RNA molecules (Figure 3) .
Taken together, these in vitro results suggest the following complementary roles for NC and IN during particle maturation: $2,000 copies of NC could coat large segments of viral RNA and thus contribute to RNP condensation while $200 copies of IN could markedly impact the architecture of RNPs, effectively compacting the two copies of viral genome by binding and bridging between several sites. Such interpretations are consistent with the CLIP-seq results that show distinct binding patterns for IN and NC to the viral RNA genome ( Figure S2 ). The combined action of both NC and IN could be required for timely formation and correct localization of the RNPs within the CA core. Alternatively, IN could mediate the correct localization of RNPs in mature virions through potential bridging interactions between the viral RNA genome and CA cores. Further studies are warranted to better understand the complex interplay between multiple viral, and possibly cellular, components during particle maturation. Surprisingly, our in vitro and in virion experiments show that IN, a double-stranded DNA binding protein, displays marked preference for highly structured RNA elements. Such structural features in the viral RNA genome could be recognized by IN and account for the highly reproducible binding pattern seen in our CLIP-seq experiments (Figures 1 and S1 ). These multiple binding sites would enable IN multimers to effectively bridge different segments of the viral RNA genome and thus promote effective compaction of RNPs. In turn, the redundancy of structural elements along the viral genome allows for the virus to compensate and to not depend on a single binding event of IN to a particular viral RNA element. For example, deletions of either TAR or RRE do not have noticeable consequences on virus particle morphogenesis (Das et al., 2007; Kutluay et al., 2014) . In addition, we note that highly structured RNA elements are also present in cellular mRNAs (Wachter, 2014) , and our in vitro assays show that IN binds human mRNA mix with low nanomolar affinity ( Figure 2F ). Therefore, it is likely that during the production of functional HIV-1-based lentiviral vector particles containing the transgenes of cellular origin, IN could interact with both viral RNA and the RNA region corresponding to the transgene to allow for effective bridging between these RNA segments.
Our site-directed mutagenesis studies have revealed both similarities and differences between IN interactions with viral DNA and viral RNA. The IN K264A/K266A substitutions impaired its ability to bind both viral DNA and viral RNA, suggesting an overlapping interface for interaction with either nucleic acid. In contrast, IN R269A/K273A mutant was unable to bind viral RNA, yet exhibited effective LEDGF/p75-mediated concerted integration activity. Another important difference between IN binding to viral DNA versus viral RNA is seen when preformed IN-nucleic acid complexes are subjected to high ionic treatments (1 M NaCl). When IN forms the SSC with cognate viral DNA, it is resistant to high ionic treatments. The formation of such a stable complex is likely to be important during the early steps of HIV-1 replication. For example, stably bound IN tetramer could protect the viral DNA ends from cellular DNA modifying enzymes and also would allow the preintegration complex to retain its integrity while traversing through the nuclear pore and associating with LEDGF/p75 and chromatin for effective integration. In contrast, IN binding to viral RNA can be reversed by high ionic treatments suggesting that there is a dynamic interplay between IN and viral RNA, which could be important for allowing HIV-1 RT to effectively reverse transcribe the viral genome.
We and others have shown that the primary mechanism of action of ALLINIs is to induce aberrant IN multimerization in virions, which leads to the formation of eccentric cores with mislocalized RNPs (Balakrishnan et al., 2013; Desimmie et al., 2013; Fontana et al., 2015; Jurado et al., 2013; Le Rouzic et al., 2013; Sharma et al., 2014 Jurado et al., 2013) . In addition, the CTD plays a critical role for ALLINI-induced aberrant IN multimerization (Gupta et al., 2014; Shkriabai et al., 2014) . In particular, our MS-based hydrogendeuterium exchange studies have revealed that ALLINI binding to the CCD promotes multiple protein-protein contacts, which include the extreme C-terminal segment (aa 249-288) (Shkriabai et al., 2014) . The identified viral RNA interacting residues (K264, K266, R269, and K273) are located within this protein segment and could be shielded in the ALLINI-induced aberrant IN multimers and are hence not available to productively engage viral RNA ( Figures S7D and S7E ). These observations coupled with our findings that ALLINIs do not affect NC binding to RNA in virions (Figures 7 and S7C ) suggest the importance of IN binding to viral RNA for proper virus particle morphogenesis.
In summary, our studies elucidate a previously undescribed non-catalytic role of IN in HIV-1 biology as it interacts with the viral RNA genome during particle morphogenesis. Furthermore, these findings significantly extend our understanding of the mechanism of action of ALLINIs, which are currently in clinical trials, and have uncovered a functionally essential interface between IN and the viral RNA genome that could serve as an attractive antiretroviral target.
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EXPERIMENTAL MODEL AND SUBJECT DETAILS
Cells
HEK293T and HeLa TZM-bl cells were grown in Dulbecco's modified eagle medium (Invitrogen), supplemented with 10% fetal bovine serum (Invitrogen), penicillin (100 I.U/mL) and streptomycin (100 mg/mL) (GIBCO) at 37 C and 5% CO2. MT-4 cells were grown in RPMI with sodium pyruvate (Invitrogen), supplemented with 10% fetal bovine serum (Invitrogen), penicillin (100 I.U/mL; GIBCO) and streptomycin (100 mg/mL; GIBCO) at 37 C and 5% CO 2 .
METHOD DETAILS
Recombinant Proteins, Synthetic RNAs, and the Inhibitor For biochemical studies recombinant proteins including 6xHis-tagged WT, K264A/K266A and R269A/K273A mutant INs as well as tag-free LEDGF/p75 were expressed in E. coli and purified by column chromatography (McKee et al., 2008) . The short synthetic RNAs were obtained from Integrated DNA Technologies. The longer vRNA(1-850) and vRNA(7350-8200) substrates were synthetized by in vitro transcription of PCR-amplified DNA regions (1-850 or 7350-8200) from the HIV-1 NL4-3 molecular clone using a MEGAscript T7 Transcription Kit (Invitrogen). Previously reported ALLINIs: BI-B2 and BI-D Wang et al., 2012) were used in the present study. Saquinavir was obtained from the AIDS-reagent program. The synthetic L50 peptide was purchased from LifeTein, LLC.
Transfection and Virion Preparations
Transfections in HEK293T cells were performed with X-tremeGENE HP (Roche) and the desired plasmid DNA (1:3 for DNA:reagent ratio). 24 hr post-transfection cells were washed and fresh media was added (with 1mM of saquinavir or DMSO for the virion processing). Cell culture supernatants containing virions were harvested 48 hr post-transfection, filtered through a 0.45 mm filter, and virions were concentrated by ultracentrifugation with a 25% sucrose cushion at 28,000 rpm for 2 hr at 4 C in SW41 rotor (Beckman). Isolated virions were assayed by HIV-1 Gag p24 ELISA (ZeptoMetrix) to determine viral production. Quantitative PCR (qPCR) was used to determine levels of genomic RNA packaged in isolated virions (Sharma et al., 2014) . Virion protein processing was analyzed by immunoblotting using an anti-CA antiserum. Levels of infectivity were monitored in TZM-bl reporter cells by assaying luciferase activity with a Luciferase Assay Kit (Promega) (Sharma et al., 2014) . The early reverse transcription products were examined as follows. The target cells were infected for 6 hr with the virus particles. The cells were harvested, the DNA was isolated with the DNeasy Blood & Tissue Kit (Quiagen) and probed with primers specific for early reverse transcription products (ERT-F and ERT-R) (Mü nk et al., 2002) . All reactions were normalized to GAPDH using SYBR-green (Maxima SYBR Green qPCR Master Mix; Thermo Scientific) based qPCR and primers specific for GAPDH. Relative quantification analysis was performed using the 2 -DDCt method (Livak and Schmittgen, 2001; Sharma et al., 2014) .
CLIP-Seq
HEK293T cells were grown in 15-cm dishes in the presence of 4SU and transfected with pNL4-3-based proviral plasmids using polyethylenimine (PolySciences). Virions were harvested from filtered supernatants by ultracentrifugation through 20% sucrose and UV-irradiated. Following lysis in RIPA buffer and RNaseA treatment, IN-RNA and NC-RNA adducts were immunoprecipitated using monoclonal antibodies against IN (Bouyac-Bertoia et al., 2001 ) and NC (Kutluay et al., 2014) . The bound RNA was end-labeled with g-32 P-ATP and T4 polynucleotide kinase. The isolated protein-RNA complexes were separated by SDS-PAGE, transferred to nitrocellulose membranes and exposed to autoradiography films. Protein-RNA complexes corresponding to IN-RNA adducts were excised from membranes and treated with proteinase K. RNA was sequentially ligated to 3 0 and 5 0 adapters (Table S1 ), reverse-transcribed, PCR-amplified and the resulting DNA library was subjected to sequencing by Illumina platforms. The data were analyzed according to (Kutluay et al., 2014) using FASTX-toolkit (http://hannonlab.cshl.edu/fastx_toolkit), Bowtie (Langmead et al., 2009) and PARalyzer (Corcoran et al., 2011) , with the exception of applying a more stringent T-to-C substitution-based cutoff for defining IN-binding sites (PARpipe). Briefly, sequencing reads were first trimmed off of the 3 0 adaptor, reads shorter than 15 nucleotides were filtered out and the library was demultiplexed based on the 5 0 adaptor sequences using the FASTX toolkit. Sequences were then collapsed into unique reads followed by trimming off the 5 0 adaptor using the FASTX toolkit. The resulting reads were mapped to the human genome (hg19) or the viral genome (HIV-1 NL4-3 ) containing a single repeat (R) region using the Bowtie algorithm by allowing two mismatches (-v 2 -m 10-best strata). Reads that mapped to the human genome were further processed and clustered by PARalyzer and PARpipe pipelines using default settings.
Electron Microscopy
Virion morphologies were monitored using thin-section transmission electron microscopy (Sharma et al., 2014; Slaughter et al., 2014) . For this, cell-free virions from transfected HEK293T cells were concentrated via ultracentrifugation at 4 C prior to fixation in 2% paraformaldehyde and submitted to the Ohio State University Campus Microscopy & Imaging Facility. Images were taken with a FEI Tecnai G2 Spirit transmission electron microscope.
HIV-1 Viral Core Analyses Using Sucrose Density Gradient Fractionation
For sucrose density gradient fractionation (Sharma et al., 2014) cell-free virions from transfected HEK293T cells were concentrated by ultracentrifugation over a 25% sucrose cushion, pelleted virions were lysed with 0.5% Triton X-100 and were ultracentrifuged through a 30%-70% linear sucrose density gradient. Fractions were collected starting from the top of the gradient and subjected to SDS-PAGE, transferred to membranes and immunoblotted with HIV-1 CA antisera to monitor the distribution of HIV-1 capsid.
Vpr-IN Transcomplementation Assays
The Vpr-IN plasmid (Kulkosky et al., 1999 ) encoding either WT IN or IN R269A/K273A was added in a ratio of 1:2 with viral plasmid HIV-1 NL4-3 or HIV-1 NL4-3 IN(R269A/K273A) to the transfection mix. The Vpr-IN fusion protein contains the viral PR cleavage site between Vpr and IN proteins, so that IN can be released during virion maturation. pCMV alone was used for empty vector control experiments. Virus particle preparations were performed as described above and normalized using HIV-1 Gag p24 ELISA (ZeptoMetrix). Virions equivalent to 5 ng p24 were then used to infect HeLa TZM-bl cells. The cells were harvested 48h post infection, lysed with 1x reporter lysis buffer (Promega) and luciferase activity was determined using a commercially available kit (Promega).
AlphaScreen-Based RNA Binding Assays
To monitor direct binding of WT IN to RNA molecules, 10 nM 6xHis-tagged IN was incubated with increasing concentrations of synthetic biotinylated RNAs at 4 C for 1 hr in the AlphaScreen buffer containing 100 mM NaCl, 1 mM MgCl 2 , 1 mM DTT, 1 mg/ml BSA, 25 mM Tris pH 7.4. The final concentration of the nickel and streptavidin AlphaScreen beads (PerkinElmer) in each well was 20 mg/mL. The AlphaScreen signal was recorded on an EnSpire Plate Reader (PerkinElmer) with an AlphaScreen module using the instrument pre-sets. Data were fitted to a Hill equation using Origin software (OriginLab, Inc.). The binding constants for unlabeled RNAs were measured by competition with a fixed concentration (10 nM) of biotinylated vRNA(1-57)-TAR substrate and the Cheng-Prusoff (Cheng and Prusoff, 1973) equation was used to calculate the K d s for the unlabeled RNAs.
AlphaScreen-Based RNA Bridging Assays Two vRNA (1-57) molecules conjugated to either biotin or DIG were mixed in the AlphaScreen buffer containing 25 mM Tris pH 7.4, 100 mM NaCl, 1 mM MgCl 2 , 1 mM DTT, 1 mg/ml BSA, and then increasing concentrations of IN or RT were added as indicated. To monitor AlphaScreen signal streptavidin coated Donor and anti-DIG Acceptor beads were added to the reaction mixture. The resulting signal was detected on an EnSpire Plate Reader (PerkinElmer) with an AlphaScreen module using the instrument pre-sets as above.
Size Exclusion Chromatography Spin Column-Based Assay for IN-Nucleic Acid Binding The previously described SEC based IN-nucleic acid binding assay (Kessl et al., 2011) was modified as follows. Recombinant IN (200 nM) was incubated with either vRNA(1-850) (100 nM) or vDNA($1 kbp) (100 nM) in the assembly buffer (100 mM NaCl, 2 mM DTT, 7.5 mM MgCl 2 , 15 mM ZnCl 2 , 12% DMSO, 10% PEG 6000, 15 mM HEPES, pH 7.5) for 3 hr at 4 C. The IN-nucleic acid complex was then purified through SEC spin columns (Biorad) equilibrated in 100 or 1000 mM NaCl, 1 mM MgCl 2 , 1 mM DTT, 20 mM HEPES pH 7.5. The excluded fractions were either analyzed by SDS-PAGE and immunoblotting, or subjected to atomic force microscopy (AFM).
AFM Analysis of the IN-vRNA(1-850) Complexes
The previously described AFM approach for analysis of IN-DNA complexes (Kotova et al., 2010; Tsuruyama et al., 2013) was modified as follows. The IN-vRNA(1-850) complexes purified by SEC spin column were adsorbed for 10 min at room temperature on freshly cleaved mica surfaces pre-coated with spermine (Andersen et al., 2004) to increase nucleic acids capture. Salts and unbound materials were removed by extensive nuclease free H 2 O washes. Samples were dried at 4 C and analyzed using a Bruker RTESPA probe mounted in a Bruker Dimension Icon Atomic Force Microscope operated in tapping mode. The AFM images were processed using Nanoscope Analysis software.
MS-Based Protein Footprinting of Surface-Accessible Lysines
The previously described MS-based approach (Kvaratskhelia and Grice, 2008) was modified as follows. IN (200 nM) was incubated with vRNA(1-57)-TAR (50 nM) in binding buffer (100 mM NaCl, 1 mM MgCl 2 , 1 mM DTT, 50 mM HEPES pH 7.5) in a 800 ml reaction volume. Reactions were incubated for 60 min at 4 C to allow for protein-nucleic acid interactions. Freshly prepared sulfo-N-hydroxysuccinimide (NHS)-biotin (Thermo Scientific) was added to the reaction at a final concentration of 40 mM and incubated at 37 C for 30 min. Reactions were quenched by adding 2.5 ml of 3 M Na-acetate, pH 5.0, containing 1 M free lysine and samples were processed and analyzed by MALDI-ToF MS (Shimadzu).
Bis(sulfosuccinimidyl)suberate Cross-linking For in vitro experiments unliganded IN or preformed IN-vRNA(1-850) complexes were exposed to 20 mM BS 3 cross-linking reagent (Thermo Scientific). To monitor the multimeric state of IN in virus particles concentrated virions (equivalent to 50 ng of HIV-1 p24) were cross-linked with 20 mM Bis(sulfosuccinimidyl) suberate (BS 3 ). The cross-linked reaction products were quenched and resolved by SDS-PAGE (4%-12%, Invitrogen) and immunoblotted using an antibody against IN.
Concerted Integration Assay
Agarose gel-based concerted integration assays (Cherepanov, 2007) were performed as follows. Viral donor DNA (1 mM, 32-mer blunt-ended U5) and target (600 ng, pBR322 plasmid) DNAs were added to 2.4 mM of WT or mutant recombinant IN proteins. Following incubation of samples at 25 C for 10 min, recombinant LEDGF/p75 was added at a final concentration of 2 mM, after which reactions proceeded for 60 min at 37 C. Activity was quenched with 25 mM EDTA and 0.5% SDS. Reactions were deproteinized with proteinase K (30 mg) treatment by incubation at 37 C for 60 min and analyzed by 1.5% agarose gel electrophoresis in 1xTAE. Reaction products were visualized by ethidium bromide staining and UV imaging.
Analytical Size Exclusion Chromatography WT, K264A/K266A and R269A/K273A mutant INs (20 mM) were analyzed with a Superdex 200 Increase 10/300 GL column (GE Healthcare) using 0.75 ml/min flow rate and the elution buffer containing 20 mM HEPES (pH 6.8), 1 M NaCl, 10 mM MgSO4, 0.2 mM EDTA, 10% glycerol, and 5 mM b-mercaptoethanol. The column was calibrated with the following proteins: conalbumin (75,000 Da), carbonic anhydrase (29,000 Da), ribonuclease A (13,700 Da), and aprotinin (6,500 Da). Proteins were detected by absorbance at 280 nm.
IN-LEDGF/p75 Binding Assay
Affinity pull-down assays (McKee et al., 2008) were performed with Ni-beads using 6xHis-tagged WT, K264A/K266A and R269A/ K273A mutant INs (2 mM) and tag-free LEDGF/p75 (2 mM). His-tagged IN was preincubated with or without tag-free LEDGF/p75 in the buffer containing 25 mm HEPES, pH 7.1, 200 mm NaCl, 4% glycerol, 2 mm b-mercaptoethanol for 30 min at room temperature. The proteins pulled-down by Ni-nitrilotriacetic acid (NTA) resin (GE Healthcare) were subjected to SDS-PAGE separation and visualized by Coomassie Blue stain.
QUANTIFICATION AND STATISTICAL ANALYSIS
The Excel software (Microsoft) was used to determine average values, standard errors and standard deviations. For each figure, number of experimental replicates and other information relevant for assessing the accuracy and precision of the analysis are included in the accompanying legend.
DATA AND SOFTWARE AVAILABILITY
Data Resources
The accession number for the raw and analyzed data reported in this paper is GEO: GSE83588. 
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